Cargando…
A Validated LC–MS/MS Assay for the Simultaneous Quantification of the FDA-Approved Anticancer Mixture (Encorafenib and Binimetinib): Metabolic Stability Estimation
The concurrent use of oral encorafenib (Braftovi, ENF) and binimetinib (Mektovi, BNB) is a combination anticancer therapy approved by the United States Food and Drug Administration (USFDA) for patients with BRAFV600E/V600K mutations suffering from metastatic or unresectable melanoma. Metabolism is c...
Autores principales: | Attwa, Mohamed W., Darwish, Hany W., Al-Shakliah, Nasser S., Kadi, Adnan A. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8125647/ https://www.ncbi.nlm.nih.gov/pubmed/34063139 http://dx.doi.org/10.3390/molecules26092717 |
Ejemplares similares
-
Identification and characterization of in vivo, in vitro and reactive metabolites of vandetanib using LC–ESI–MS/MS
por: Attwa, Mohamed W., et al.
Publicado: (2018) -
Investigation of the metabolic stability of olmutinib by validated LC-MS/MS: quantification in human plasma
por: Attwa, Mohamed W., et al.
Publicado: (2018) -
Validated LC-MS/MS Method for the Quantification of Ponatinib in Plasma: Application to Metabolic Stability
por: Kadi, Adnan A., et al.
Publicado: (2016) -
LC-MS/MS Estimation of the Anti-Cancer Agent Tandutinib Levels in Human Liver Microsomes: Metabolic Stability Evaluation Assay
por: Attwa, Mohamed W, et al.
Publicado: (2020) -
LC-ESI-MS/MS reveals the formation of reactive intermediates in brigatinib metabolism: elucidation of bioactivation pathways
por: Kadi, Adnan A., et al.
Publicado: (2018)